Sign in
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study (vol 22, pg 85, 2021)
Journal article   Peer reviewed

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study (vol 22, pg 85, 2021)

A. R. Tan, S-A Im and A. Mattar
The lancet oncology, Vol.22(2), pp.E42-E42
01/02/2021

Abstract

Life Sciences & Biomedicine Oncology Science & Technology

Metrics

1 Record Views

Details